How These 2 Nasdaq-Listed Marijuana Companies Found A Way To Raise $250M Without Tanking Their Stock
This week's Viridian Valuation Tracker investigates the valuation metrics of Canadian cultivation and retail companies with market caps over $100M. The focus is on Canopy Growth (NASDAQ:CGC) and Tilra
Catalyst Watch: Apple's WWDC, Tesla's Annual Meeting, Fed's Dot Plot, and GameStop Volatility
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Germany Sets THC Limits For Drivers, Opposition Groups Say It's Too High
Lawmakers in Germany have set a maximum allowed limit of THC – the psychoactive substance found in the cannabis plant – for drivers to have in the blood.The Bundestag, the country's lower house of par
AbbVie, Amazon, Goldman Sachs And 2 Major Health Care Stocks On CNBC's 'Final Trades'
On CNBC's "Halftime Report Final Trades," Jim Lebenthal of Cerity Partners said AbbVie Inc. (NYSE:ABBV) is a very solid pharmaceutical company. The company has good dividend yield and attractive valua
AbbVie-partnered Therapy Selected for FDA's Rare Disease Pilot Program
Gamestop's pre-market stock price has fluctuated dramatically, will the leader return to the live broadcast tonight? Can they lead the Meme stock to another frenzy?
Keith Gill, the leader of the meme stock movement (codenamed "Roaring Kitty"), will return to YouTube for a live broadcast at 12pm EDT on June 7th (12am HKT on June 8th), marking his return to the platform after a three-year hiatus.
"Lead Big Brother" manipulating the market? Regulators: lack of evidence, prosecution is unfounded.
Did the leader use their personal influence to manipulate the stock price of meme, and then profit greatly from it? Would this be considered market manipulation? If the SEC wants to prosecute them for market manipulation, they need evidence that the leader deceived investors to some extent, but currently the SEC lacks such evidence.
Bearish Sentiment Across The Cannabis Space - Check Full Movers For June 6, 2024
GAINERS:MJ Holdings (OTC:MJNE) shares closed up 50.94% at $0.01Global Hemp Group (OTC:GBHPF) shares closed up 33.33% at $0.04CNBX Pharmaceuticals (OTC:CNBX) shares closed up 17.69% at $0.011933 Indust
Thermo Fisher Scientific's Options Frenzy: What You Need to Know
Whales with a lot of money to spend have taken a noticeably bullish stance on Thermo Fisher Scientific.Looking at options history for Thermo Fisher Scientific (NYSE:TMO) we detected 27 trades.If we co
AbbVie's Immunogen Acquired Elahere Meets Primary Goal In Mid-Stage Study In Heavily Pretreated Ovarian Cancer Patients
On Thursday, AbbVie Inc (NYSE:ABBV) released topline results from the Phase 2 PICCOLO trial evaluating investigational mirvetuximab soravtansine (Elahere) monotherapy in heavily pre-treated patients w
CNBC Halftime Report Final Trades: Amazon.Com, The Goldman Sachs Group, IQVIA Holdings, AbbVie
CNBC Halftime Report Final Trades: Amazon.Com, The Goldman Sachs Group, IQVIA Holdings, AbbVie
Tilray Ramps Up Its Cannabis Portfolio In Canada, Wins International Spirits Competition
Tilray Brands, Inc. (NASDAQ:TLRY) (TSX:TLRY) announced on Thursday the launch of 'Purple Churro,' by Redecan cannabis.The new sativa offers "a sweet, indulgent experience with a potent twist and boast
AbbVie Succeeds in Mid-stage Trial for Overran Cancer Drug, Elahere
AbbVie Doses First Patient in Phase 3 Trial of Multiple Myeloma Asset
Aurora Cannabis Launches 1.2g Resign Cartridges In Australia, Now Available For Doctors To Prescribe
Canadian cannabis giant Aurora Cannabis Inc.(NASDAQ:ACB) (TSX:ACB) in conjunction with MedReleaf Australia, is launching its premium 1.2g resin cartridges in Australia. Now available for doctors to pr
AbbVie Treats First Patient With Investigational ABBV-383 In Phase 3 CERVINO Study For Relapsed/Refractory Multiple Myeloma
ABBV-383 is a B-cell maturation antigen (BCMA) bispecific antibody T-cell engager being evaluated in relapsed/refractory multiple myeloma (r/r MM)The CERVINO Phase 3 trial will evaluate the efficacy,
Top 4 Health Care Stocks That Are Preparing To Pump This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock's strength on days when prices go u
HSBC Upgrades AbbVie to Buy, Announces $185 Price Target
HSBC analyst Rajesh Kumar upgrades AbbVie (NYSE:ABBV) from Hold to Buy and announces $185 price target.
AbbVie Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/05/2024 13.14% HSBC → $185 Upgrades Hold → Buy 05/17/2024 22.32% Cantor Fitzgerald → $200 Initiates Cov